Praxis Precision Medicines, Inc. PRAX Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Praxis Precision Medicines, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The official record: Praxis Precision Medicines, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Praxis Precision Medicines, Inc.'s total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Praxis Precision Medicines, Inc.'s total current liabilities?
- Praxis Precision Medicines, Inc. (PRAX) reported total current liabilities of $50.24M in Q1 2026.
- How has Praxis Precision Medicines, Inc.'s total current liabilities changed year-over-year?
- Praxis Precision Medicines, Inc.'s total current liabilities increased by 27.1% year-over-year, from $39.52M to $50.24M.
- What is the long-term trend for Praxis Precision Medicines, Inc.'s total current liabilities?
- Over 5 years (2020 to 2025), Praxis Precision Medicines, Inc.'s total current liabilities has grown at a 30.6% compound annual growth rate (CAGR), from $15.72M to $59.77M.
- What does total current liabilities mean?
- The total debt and obligations due within the next twelve months.
- How do you interpret total current liabilities?
- An increase suggests higher short-term pressure on cash reserves, while a decrease indicates reduced immediate debt burden.
- How does total current liabilities compare across companies?
- Peers in the biotech sector typically maintain low current liabilities relative to cash, though this fluctuates based on clinical trial activity.